Low-dose IL-2 expands CD4 ⁺ regulatory T cells with a suppressive function <i>in vitro via</i> the STAT5-dependent pathway in patients with chronic kidney diseases

Abstract

Our findings support the clinical Treg defects in CKD patients with glomerular diseases, and the rationale of evaluating low-dose IL-2 treatment for selectively modulating CD4⁺ Tregs.